NeuroPace, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NeuroPace, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-60.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 75% of Healthcare companies in United States.
Cash Locked Ratio
$29For every $100 of sales, $29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $33 tied up three years earlier.
More money tied up than 64% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$47Sales grew 120% in 3 years; of every extra $100 of sales, $47 became extra profit.
Higher than 69% of Healthcare companies in United States.
Asset Productivity Ratio
+120% / -7%In 3 years sales changed by +120% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-5.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 59% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 71% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
NeuroPace, Inc. made a loss over the last year. NeuroPace, Inc. owes $0.88 for every $1 it owns. NeuroPace, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNeuroPace, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
37.96The share price is 37.96 times NeuroPace, Inc.'s book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$451 MThe total market value of all of NeuroPace, Inc.'s shares at today's price (share price × number of shares), larger than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$12 MWhat NeuroPace, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.35Net worth divided by the number of shares. The share price of $13.14 is 38.0 times this, which is the P/B above.
Return on equity (ROE)
-103.3%NeuroPace, Inc. lost 103.3% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
Owes vs Owns
0.88×NeuroPace, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Dividend yield
NoneNeuroPace, Inc. does not currently pay a dividend.
Revenue growth
+25%Revenue rose 25% in the year to Dec 2025, and grew 30% a year on average over 3 years.
Profit growth
LossNeuroPace, Inc. made a loss in each of the last two years.
Profit margin
-21.5%NeuroPace, Inc. lost $21 for every $100 of revenue.
Interest cover
Not coveredNeuroPace, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtNeuroPace, Inc. had $10 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NeuroPace, Inc.: $451 M ÷ $12 M (30 Jun 2026) = 38.0.
What is NeuroPace, Inc.'s return on equity?
NeuroPace, Inc. lost 103.3% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
How much does NeuroPace, Inc. owe compared with what it owns?
NeuroPace, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Does NeuroPace, Inc. pay a dividend?
No. NeuroPace, Inc. does not currently pay a dividend.
Is NeuroPace, Inc.'s revenue growing?
Revenue rose 25% in the year to Dec 2025, and grew 30% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.